Efficacy of cognitive pragmatic treatment in adults with schizophrenia

被引:1
|
作者
Muthu, Anusuya [1 ]
Nambi, Shanthi [2 ]
Krishnan, Raman [2 ]
Vijayaraghavan, Rajagopalan [3 ]
机构
[1] Saveetha Med Coll & Hosp, Dept Speech Language & Hearing Sci ENT, Chennai, Tamil Nadu, India
[2] Saveetha Med Coll & Hosp, Dept Psychiat, Chennai, Tamil Nadu, India
[3] Saveetha Inst Med & Tech Sci, Dept Res & Dev, Chennai, Tamil Nadu, India
关键词
Schizophrenia; cognitive pragmatic treatment; cognitive functioning; pragmatic language impairment; group therapy; social communication impairment; ANTIPSYCHOTIC MEDICATION; LANGUAGE; DEFICITS; EXPRESSION; THERAPY; SKILLS;
D O I
10.54905/disssi/v27i132/e100ms2828
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objectives: The study aimed to evaluate the efficiency of cognitive-pragmatic treatment (CPT) in improving cognitive functions and pragmatic language abilities in adults with schizophrenia. Methods: 100 individuals with schizophrenia who fulfilled the inclusion criteria were assigned to control (n = 25) and experimental groups (n = 75). Experimental groups received CPT for 3 months, while the control group obtained only routine care. Individuals were tested both before and after the intervention to gauge their progress also 3 months post-intervention, a follow-up evaluation was carried out. Analyses employed parametric and non-parametric statistics. Results: The findings revealed significant variations among groups and tests (p<0.001), & interaction of groups with tests (p<0.001) on two-way Repeated Measures ANOVA. Both the post-test and the follow-up assessment indicated that the experimental group had significantly higher levels of pragmatic language skills and cognitive functioning than the control group. There has been no major influence of age, gender and illness duration on the treatment outcomes by three-way ANOVA. Conclusions: The present study showed that CPT improved pragmatic language communication skills & cognitive functioning in adults with schizophrenia.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] A Meta-analysis of Cognitive Remediation for Schizophrenia: Efficacy and the Role of Participant and Treatment Factors
    Lejeune, Julia A.
    Northrop, Andrew
    Kurtz, Matthew M.
    SCHIZOPHRENIA BULLETIN, 2021, 47 (04) : 997 - 1006
  • [22] Efficacy of new antipsychotics on cognitive functions in schizophrenia
    Peuskens, J
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2002, 12 : S148 - S148
  • [23] Predicting drug efficacy for cognitive deficits in schizophrenia
    Hagan, JJ
    Jones, DNC
    SCHIZOPHRENIA BULLETIN, 2005, 31 (04) : 830 - 853
  • [24] Cognitive Retraining and Functional Treatment (CRAFT) for adults with cancer related cognitive impairment: a preliminary efficacy study
    Maeir, Talia
    Makranz, Chen
    Peretz, Tamar
    Odem, Ester
    Tsabari, Shani
    Nahum, Mor
    Gilboa, Yafit
    SUPPORTIVE CARE IN CANCER, 2023, 31 (03)
  • [25] Cognitive Retraining and Functional Treatment (CRAFT) for adults with cancer related cognitive impairment: a preliminary efficacy study
    Talia Maeir
    Chen Makranz
    Tamar Peretz
    Ester Odem
    Shani Tsabari
    Mor Nahum
    Yafit Gilboa
    Supportive Care in Cancer, 2023, 31
  • [26] Cognitive abilities and theory of mind in explaining communicative pragmatic disorders in patients with schizophrenia
    Parola, Alberto
    Berardinelli, Laura
    Bosco, Francesca M.
    PSYCHIATRY RESEARCH, 2018, 260 : 144 - 151
  • [27] Cognitive skills group treatment for schizophrenia
    Ahmed, M
    Boisvert, CM
    PSYCHIATRIC SERVICES, 2002, 53 (11) : 1476 - 1477
  • [28] Donepezil in the treatment of cognitive dysfunction in schizophrenia
    Tuma, I
    Pérez, M
    Lenderova, Z
    Zemanova, M
    Kadlecova, E
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S227 - S228
  • [29] On the trail of a cognitive enhancer for the treatment of schizophrenia
    Stip, E
    Chouinard, S
    Boulay, LJ
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2005, 29 (02): : 219 - 232
  • [30] Guanfacine treatment of cognitive impairment in schizophrenia
    Friedman, JI
    Adler, DN
    Temporini, HD
    Kemether, E
    Harvey, PD
    White, L
    Parrella, M
    Davis, KL
    NEUROPSYCHOPHARMACOLOGY, 2001, 25 (03) : 402 - 409